Future Market Insights has announced the addition of the Liquid Biopsy Market,2016-2026
Future Market Insights has announced the addition of the “Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering.
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.
Liquid Biopsy Market: Drivers and Restraints
Foremost drivers for the liquid biopsy market include. Factors such as tolerability and patient convenience are promoting adoption of liquid biopsies. Liquid biopsy procedures are replacing tissue diagnosis procedures which often is not possible through tissue biopsy in cases of non-small cell lung cancers. Clinical trial conducted by the companies have been noted that the liquid biopsies could also help in detection of cancer in its early stage of than arrival of particular symptoms. This could lead to provision of a longer treatment horizon and better chances of elongating the survival period of the patient.
Request free sample Report: www.futuremarketinsights.com/reports/sample/rep-gb-1396
Lack of documented evidence about the efficacy of the process, cost-intensive nature of the research process that leads to frequent clinical trial abandonment and dearth of people with specialized knowledge on the same are the factor hindering the growth of liquid biopsy market. Countries with limited capital investment in R&D infrastructure and dearth of skilled professionals, would largely influences the development pace of the technology and thus its establishment as a preferred biopsy method.
Liquid Biopsy Market: Segmentation
Biosimilars and Follow-on Biologics Market can be segmented into these following ways:
Ø Segmentation by approach of diagnosis
§ Circulating Tumor Cells (CTC)
§ Circulating Tumor DNA (ctDNA)
§ RNA in exosomes
§ Extra-cellular vesicles (EVs)
Ø Segmentation by type of cancer application
§ Lung cancer
§ Pancreatic cancer
§ Other visceral (deeply located) cancers
Ø Segmentation by channel participants
§ Cancer Centers and Hospitals
§ Contract Research Organizations
§ Academic Institutions
§ Specialized research laboratories
Request for TOC:www.futuremarketinsights.com/toc/rep-gb-1396
Liquid Biopsy Market: Overview
The revolutionary nature of liquid biopsy procedure is expected to create noise in the field of tissue biopsy and innovative cancer diagnosis in near future. Large drug makers are increasing entering into collaborative partnerships with leading academic institutions such as Dana Farber Cancer Research Institute, University of Oxford, U.S. National Cancer Institute, and others to increase the rapidity of research in liquid biopsy. The current prospect of the market is however limited to developed countries in the world but is expected to exhibit significantly high CAGR over a ten-year forecast period.
Liquid Biopsy Market: Region-wise Outlook
Depending on geographic regions, liquid biopsy market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. All major action in the field of liquid biopsy is expected to emerge from North America and Europe region over the forecast period. However, with development of sophisticated R&D infrastructure in emerging region such as APAC, is expected to gain traction supported through gradual availability of low-cost meaningful liquid biopsy option in cancer diagnosis. Other factors expected to prominent impact on the growth of liquid biopsy are increasing patient awareness and affordability levels & regulatory harmonization. However, increasing funding for private public partnerships in field of cancer research is expected to fuel the adoption of liquid biopsy over the forecast period. Moreover, the rising disease incidence of lung and pancreatic cancer in all major regions of the world is expected to drive the growth of liquid biopsy market.
Browse full report: www.futuremarketinsights.com/reports/liquid-biopsy-market
Liquid Biopsy Market: Key Players
Some of the key players in the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU among others.